Tirzepatide Shows Significant Potential in Reducing Alcohol Consumption, Study Finds

A new study indicates that tirzepatide, the active ingredient in Mounjaro, significantly reduces alcohol consumption and prevents relapse-like behavior in animal models. Researchers at the University of Gothenburg published these compelling findings in the journal eBioMedicine.

Key Findings

Animals treated with tirzepatide consumed over 50% less alcohol and did not increase consumption after abstinence, preventing relapse-like drinking.

Animals treated with tirzepatide consumed over 50% less alcohol compared to control groups. The drug also prevented relapse-like drinking; after a period of abstinence, treated animals did not increase their consumption.

Tirzepatide appears to function by attenuating alcohol-induced dopamine spikes in the brain's reward system, specifically in the lateral septum, a brain region linked to motivation and addiction. This mechanism may reduce the reinforcing properties of alcohol.

Unlike semaglutide (Ozempic), which targets only GLP-1, tirzepatide is a dual agonist (GIP and GLP-1), which researchers suggest may offer a more robust effect on addictive behaviors.

The study identified changes in histone-related proteins in the lateral septum, which influence gene expression. While these changes do not directly prove a causal link to reduced alcohol consumption, they suggest potential long-term biological shifts in how the brain processes rewards.

Implications for Future Treatment

Tirzepatide's existing approval for type 2 diabetes and weight loss means its safety profile is well-understood, potentially accelerating future research into its application for alcohol use disorder.

While these findings are from animal models and do not yet constitute a new treatment for alcohol use disorder, tirzepatide's existing approval for type 2 diabetes and weight loss means its safety profile is well-understood. This could potentially accelerate future research into its application for alcohol use disorder. Researchers suggest further investigation into drugs targeting these neural systems as potential treatment options.